Research progress on pharmacogenomics of daunorubicin individual differences

Abstract

Abstract: Daunorubicin is a clinical anti-leukemia drug.The effect is significant but there are significant individual differences. How to learn more about the factors that may cause daunorubicin resistant,thereby improving the efficacy of daunomycin, reducing resistance, and reducing the side effects of the drug, is a concern of clinical worker. This article reviews the genetic factors that affect daunorubicin pharmacokinetics and pharmacodynamics and provides some reference for daunorubicin individualized clinical administration .

Key words: Daunorubicin, Gene polymorphism, Leukemia

CLC Number:

R969

HE Hui, ZHOU Hong-hao, LIU Zhao-qian. Research progress on pharmacogenomics of daunorubicin individual differences[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1182-1185.

References

[1] Roumier C, Cheok MH. Pharmacogenomics in acute myeloid leukemia[J]. Pharmacogenomics, 2009,10(11): 1839-1851.
[2] O'Donnell MR, Brown PA, Aoun P, et al. Acute myeloid leukemia[J]. J Natl Compr Canc Netw,2012, 10(8):984-1021.
[3] Alvarnas JC, Abboud CN, Altman J, et al. Acute lymphoblastic leukemia[J]. J Natl Compr Canc Netw, 2012,10(7):858-914.
[4] Quiney C, Billard C, Faussat AM, et al. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells[J]. Leuk Lymphoma, 2007, 48(8): 1587-1599.
[5] Szuławska A, Czyz M. Molecular mechanisms of anthracyclines action[J]. Postepy Hig Med Dosw , 2006,60: 78-100.
[6] Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia[J]. Cancer Cell, 2005, 7(4): 375-386.
[7] Holleman A, Cheok MH, den Boer ML, et al.Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment[J]. N Engl J Med, 2004, 351(6): 533-542.
[8] Hodges LM, Markova SM, Chinn LW,et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)[J]. Pharmacogenet Genomics,2011, 21(3): 152-161.
[9] Dantzig, AH, Law KL, Cao J, et al. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic[J]. Curr Med Chem, 2001, 8(1): 39-50.
[10] Dey S. Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition[J]. Expert Opin Drug Deliv, 2006, 3(1): 23-35.
[11] Yin JY, Huang Q, Yang Y, et al.Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population[J]. Pharmacogenet Genomics, 2009,19(3): 206-216.
[12] Green H,Falk IJ, Lotfi K,et al.Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype[J]. Pharmacogenomics J, 2012,12(2): 111-118.
[13] Jeong H, Herskowitz I, Kroetz DL, et al. Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay[J]. PLoS Genet, 2007, 3(3): e39.
[14] Bains OS, Karkling MJ, Lubieniecka JM, et al. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism[J]. J Pharmacol Exp Ther,2012, 332(3): 755-763.
[15] Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy[J]. Cardiovasc Toxicol, 2007, 7(2): 56-60.
[16] Visscher H, Ross CJ, Rassekh SR,et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children[J]. J Clin Oncol,2012, 30(13): 1422-1428.
[17] Fan L, Goh BC, Wong CI,et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity[J]. Pharmacogenet Genomics, 2008,18(7): 621-631.
[18] Rajic V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood[J]. Leuk Lymphoma, 2009, 50(10): 1693-1698.
[19] Blanco JG, Aplenc R, Debeljak M,et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children's Oncology Group[J]. J Clin Oncol,2012, 30(13): 1415-1421.
[20] Mahlknecht U, Dransfeld CL, Bulut N, et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival[J]. Leukemia, 2009, 23(10): 1929-1932.
[21] Huang RS, Duan S, Kistner EO,et al. Genetic variants contributing to daunorubicin-induced cytotoxicity[J]. Cancer Res, 2008, 68(9): 3161-3168.
[22] Amitai Y, Bhooma T, Frischer H. Glucose-6-phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes[J]. J Lab Clin Med, 1996, 127(6): 588-598.
[23] Baer-Dubowska W, Majchrzak-Celinska A,Cichocki M. Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs[J]. Pharmacol Rep,2012,63(2): 293-304.
[24] Duan S, Bleibel WK, Huang RS, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity[J]. Cancer Res, 2007, 67(11): 5425-5433.
[25] Gamazon ER Huang RS, Cox NJ, et al. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci[J]. Proc Natl Acad Sci USA,2012,107(20): 9287-9292.